TRUMENBA (Meningococcal Group B Vaccine) is Now Available

November 18, 2014 Pfizer Inc. announced today that TRUMENBA® (Meningococcal Group B Vaccine), the first and only FDA-approved vaccine for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B in individuals 10 through 25 years of age, is now available for order by healthcare providers in the United States. Serogroup B meningococcal meningitis is characterized by high fatality rates and …

Novartis Receives Australian Approval for Bexsero

Novartis Bexsero® meningitis B vaccine receives clinical recommendation for use in infants and adolescents in Australia March 13, 2014 Novartis has announced that Australia has joined the growing number of countries where following licensure, Bexsero® (Meningococcal Group B Vaccine [rDNA, component, adsorbed]) has received a clinical recommendation for the vaccine’s routine use to help protect against meningitis B. These recommendations follow recent access milestones for Bexsero in multiple …

Novartis provides second US university with Bexsero

February 24, 2014 Novartis announced today that its meningococcal serogroup B (MenB) vaccine, Bexsero (Meningococcal Group B Vaccine [rDNA, component, adsorbed]), will be used as part of a vaccination program at the University of California Santa Barbara (UCSB) that began today and will end on March 7. In the last three months, the Food and Drug Administration (FDA) has approved …